Carbonic acid 4-nitrophenyl 5-thiazolylmethyl ester

Min.Order / FOB Price:Get Latest Price

10 Gram	Negotiable

10 Gram

Negotiable

Min.Order :10 Gram
Purity: 99%
Payment Terms : T/T,Other

Keywords

Carbonic acid 4-nitrophenyl 5-thiazolylmethyl ester 5-Thiazolyl)methyl)-(4-nitrophenyl)carbonate supplier 144163-97-3

Quick Details

Appearance:white powder
Application:APIs, pharmaceutical intermediates
PackAge:Aluminous bag or plastic bags
ProductionCapacity:1000|Kilogram|Day
Storage:Store in dry,dark,ventilated place
Transportation:By Sea or By Air

Superiority:

Shanghai LONGBANG , Boasts strong competitive advantages by our well-trained chemists with rich professional backgroud. We aim to win the market via quick response and fast delivery, as well as continous development for high-tech medical compounds, bio-medicine, and new pharmaceutical intermediates.

- Our quality assurance system is based on GMP.

- Products are exported to all over the world: USA, Europe, South Asia, Middle East and so on, also has established long term and stable business relationships with our customers.

- Fast delivery

- High quality, Preferential price

Details:

5-Thiazolyl)methyl)-(4-nitrophenyl)carbonate 

Purity: 99% 

CAS No.: 144163-97-3 

Grade: Pharmceutical Grade 

Lead Time: 1-2 days upon receipt of payment 

Delivery Time: Usually 4-6 working days by air 

Storage: Refrigerator 

Usage: API, intermediate for Ritonavir, one kind of anti-AIDS drug 



Product description: 



MF: C11H8N2O5S 

MW: 280.26 

Assay ≥ 99.0% 

Appearance: Pale-Yellow Solid 

Moisture: ≤ 0.5% 

Melting point: 126-127 ° C 

Boiling point: 475.333 ° C at 760 mmHg 

Refractive index: 1.627 

Density: 1.485 



About Ritonavir: 



Ritonavir, is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS. 

Ritonavir is frequently prescribed with HAART, not for its antiviral action, but as it inhibits the same host enzyme that metabolizes other protease inhibitors. This inhibition leads to higher plasma concentrations of these latter drugs, allowing the clinician to lower their dose and frequency and improving their clinical efficacy.